Importance of the Initial Volume of Parotid Glands in Xerostomia for Patients with Head and Neck Cancers Treated with IMRT
Open Access
- 23 June 2005
- journal article
- research article
- Published by Oxford University Press (OUP) in Japanese Journal of Clinical Oncology
- Vol. 35 (7), 375-379
- https://doi.org/10.1093/jjco/hyi108
Abstract
Objective: Our aim was to evaluate predictors of xerostomia in patients with head and neck cancers treated with intensity-modulated radiation therapy (IMRT). Methods: Thirty-three patients with pharyngeal cancer were evaluated for xerostomia after having been treated with IMRT. All patients were treated with whole-neck irradiation of 46–50 Gy by IMRT, followed by boost IMRT to the high-risk clinical target volume to a total dose of 56–70 Gy in 28–35 fractions (median, 68 Gy). For boost IMRT, a second computed tomography (CT-2) scan was done in the third to fourth week of IMRT. Xerostomia was scored 3–4 months after the start of IMRT. Results: The mean doses to the contralateral and ipsilateral parotid glands were 24.0 ± 6.2 and 30.3 ± 6.6 Gy, respectively. Among the 33 patients, xerostomia of grades 0, 1, 2 and 3 was noted in one, 18, 12 and two patients, respectively. Although the mean dose to the parotid glands was not correlated with the grade of xerostomia, the initial volume of the parotid glands was correlated with the grade of xerostomia (P = 0.04). Of 17 patients with small parotid glands (≤38.8 ml) on initial CT (CT-1), 11 (65%) showed grade 2 or grade 3 xerostomia, whereas only three (19%) of 16 patients with larger parotid glands showed grade 2 xerostomia (P < 0.05). The mean volume of the parotid glands on CT-1 was 43.1 ± 15.2 ml, but decreased significantly to 32.0 ± 11.4 ml (74%) on CT-2 (P < 0.0001). Conclusions: Initial volumes of the parotid glands are significantly correlated with the grade of xerostomia in patients treated with IMRT. The volume of the parotid glands decreased significantly during the course of IMRT.Keywords
This publication has 14 references indexed in Scilit:
- Quality of life after parotid-sparing IMRT for head-and-neck cancer: A prospective longitudinal studyInternational Journal of Radiation Oncology*Biology*Physics, 2003
- Feasibility Study of the Simultaneous Integrated Boost (SIB) Method for Malignant Gliomas Using Intensity-modulated Radiotherapy (IMRT)Japanese Journal of Clinical Oncology, 2003
- Phase I study of weekly docetaxel infusion and concurrent radiation therapy for head and neck cancer.Japanese Journal of Clinical Oncology, 2003
- Dosimetric predictors of xerostomia for head-and-neck cancer patients treated with the smart (simultaneous modulated accelerated radiation therapy) boost techniqueInternational Journal of Radiation Oncology*Biology*Physics, 2003
- Intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma: an update of the UCSF experienceInternational Journal of Radiation Oncology*Biology*Physics, 2002
- Protection of salivary function by intensity-modulated radiation therapy in patients with head and neck cancerSeminars in Radiation Oncology, 2002
- Intensity-modulated radiation therapy reduces late salivary toxicity without compromising tumor control in patients with oropharyngeal carcinoma: a comparison with conventional techniquesRadiotherapy and Oncology, 2001
- Partial irradiation of the parotid glandSeminars in Radiation Oncology, 2001
- A prospective study of salivary function sparing in patients with head-and-neck cancers receiving intensity-modulated or three-dimensional radiation therapy: initial resultsInternational Journal of Radiation Oncology*Biology*Physics, 2001
- Parotid gland function during and following radiotherapy of malignancies in the head and neck: A consecutive study of salivary flow and patient discomfortEuropean Journal of Cancer, 1992